NEW YORK, Oct. 22, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Medtronic Plc (“”Medtronic” or the “Company”) (NYSE: MDT).   Such investors are advised to contact Robert S. Willoughby at  newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Medtronic and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On December 15, 2021, Medtronic disclosed receipt of a warning letter from the U.S. Food and Drug Administration (“FDA”) regarding its Northridge, California facility (the “Warning Letter”).  The Warning Letter followed an FDA inspection relating to the Company’s MiniMed 600 series recall and focused on “the inadequacy of specific medical device quality system requirements . . . in the areas of risk assessment, corrective …

Full story available on Benzinga.com